UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

~~FORM~~Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~November~~March ~~2023~~2024

Commission File Number 000-50112

RepliCel Life Sciences Inc.

(Translation of registrant's name into English)

Suite 900 - 570 Granville Street, Vancouver, British Columbia V6C 3P1

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [X] Form 40-F [ ]

Indicate by check mark if the registrant is submitting the Form 206-FK ☒in ~~Form~~paper 40as permitted by Regulation S-FT ☐Rule 101(b)(1) [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐____

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

- 2 -

SUBMITTED HEREWITH

Exhibit		Description
99.1	News Release dated March 18, 2024.
99.1		Condensed Consolidated Interim Financial Statements for the period ended September 30, 2023
99.2	Material Change Report dated March 20, 2024.
99.2		Management Discussion and Analysis for the period ended September 30, 2023
99.3		Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate - CEO
99.4		Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate - CFO

- 3 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

RepliCel Life Sciences Inc.

/s/ Andrew Schutte

Andrew ~~SchuttePresident~~Schutte, ~~Chief Executive Officer and Director~~President

Date: March ~~November 29~~20, ~~2023~~2024

Filing Compare · REPLICEL LIFE SCIENCES INC.